[{"id":"9c255554-467f-443d-b9bf-0883f980d302","acronym":"SGNB6A-001","url":"https://clinicaltrials.gov/study/NCT04389632","created_at":"2021-08-12T17:53:41.583Z","updated_at":"2025-02-25T13:53:17.348Z","phase":"Phase 1","brief_title":"A Study of SGN-B6A in Advanced Solid Tumors","source_id_and_acronym":"NCT04389632 - SGNB6A-001","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)"],"overall_status":"Recruiting","enrollment":" Enrollment 824","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2025-02-20"},{"id":"eb00d46f-58b9-465f-bc29-d7ac0dc998a2","acronym":"Be6A Lung-01","url":"https://clinicaltrials.gov/study/NCT06012435","created_at":"2023-08-25T15:08:41.304Z","updated_at":"2025-02-25T13:55:31.343Z","phase":"Phase 3","brief_title":"A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (Be6A Lung-01).","source_id_and_acronym":"NCT06012435 - Be6A Lung-01","lead_sponsor":"Seagen Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • sigvotatug vedotin (PF-08046047)"],"overall_status":"Recruiting","enrollment":" Enrollment 560","initiation":"Initiation: 02/21/2024","start_date":" 02/21/2024","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2025-02-20"}]